Top

Annals of Nuclear Medicine

Published in:

01-05-2014 | Short Communication

FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma

Authors: Marcus D. Goncalves, Abass Alavi, Drew A. Torigian

Published in: Annals of Nuclear Medicine | Issue 4/2014

Abstract

Objectives

To quantify the differential effects of chemotherapy on the metabolic activity of skeletal muscle in vivo using molecular imaging with [18F]-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT).

Methods

In this retrospective study, 21 subjects with stage IV melanoma who underwent pre- and post-chemotherapy whole-body FDG-PET/CT imaging were included. The mean standardized uptake value (SUV_mean) of 8 different skeletal muscles was measured per subject. Pre- and post-treatment measurements were then averaged across all subjects for each muscle and compared for statistically significant differences between the muscles and following different chemotherapy regimens including dacarbazine (DTIC) and temozolomide (TMZ).

Results

Analysis of FDG-PET/CT images reliably detected changes in skeletal muscle metabolic activity based on muscle location. The percent change in metabolic activity of each skeletal muscle in each subject following chemotherapy was observed to be related to the type of chemotherapy received. Subjects receiving DTIC generally had a decrease in metabolic activity of all muscle groups, whereas subjects receiving TMZ generally had an increase in muscle activity of all muscle groups.

Conclusion

FDG-PET/CT can reveal baseline metabolic differences between different muscles of the body. Different chemotherapies are associated with differential changes in the metabolic activity of skeletal muscle, which can be detected and quantified with FDG-PET/CT.

Available only for authorised users

Kelley DE, Price JC, Cobelli C. Assessing skeletal muscle glucose metabolism with positron emission tomography. IUBMB Life. 2001;52(6):279–84.PubMedCrossRef

Selberg O, Muller MJ, van den Hoff J, Burchert W. Use of positron emission tomography for the assessment of skeletal muscle glucose metabolism. Nutrition. 2002;18(4):323–8.PubMedCrossRef

Wehrli NE, Bural G, Houseni M, Alkhawaldeh K, Alavi A, Torigian DA. Determination of age-related changes in structure and function of skin, adipose tissue, and skeletal muscle with computed tomography, magnetic resonance imaging, and positron emission tomography. Semin Nucl Med. 2007;37(3):195–205.PubMedCrossRef

Kwee TC, Torigian DA, Alavi A. Overview of positron emission tomography, hybrid positron emission tomography instrumentation, and positron emission tomography quantification. J Thorac Imaging. 2013;28(1):4–10.PubMedCrossRef

Kwee TC, Basu S, Saboury B, Alavi A, Torigian DA. Functional oncoimaging techniques with potential clinical applications. Front Biosci (Elite Ed). 2012;4:1081–96.PubMedCrossRef

Fujimoto T, Kemppainen J, Kalliokoski KK, Nuutila P, Ito M, Knuuti J. Skeletal muscle glucose uptake response to exercise in trained and untrained men. Med Sci Sports Exerc. 2003;35(5):777–83.PubMedCrossRef

Kemppainen J, Fujimoto T, Kalliokoski KK, Viljanen T, Nuutila P, Knuuti J. Myocardial and skeletal muscle glucose uptake during exercise in humans. J Physiol. 2002;542(Pt 2):403–12.PubMedCentralPubMedCrossRef

Pappas GP, Olcott EW, Drace JE. Imaging of skeletal muscle function using (18)FDG PET: force production, activation, and metabolism. J Appl Physiol. 2001;90(1):329–37.PubMed

Masud MM, Fujimoto T, Miyake M, Watanuki S, Itoh M, Tashiro M. Redistribution of whole-body energy metabolism by exercise: a positron emission tomography study. Ann Nucl Med. 2009;23(1):81–8.PubMedCrossRef

10.

Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Investig. 2004;114(3):370–8.PubMedCentralPubMedCrossRef

11.

Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2(11):862–71.PubMedCrossRef

12.

Le Bricon T, Gugins S, Cynober L, Baracos VE. Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats. Metab Clin Exp. 1995;44(10):1340–8.PubMedCrossRef

13.

Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC, Attaix D. Higher skeletal muscle protein synthesis and lower breakdown after chemotherapy in cachectic mice. Am J Physiol Regul Integr Comp Physiol. 2001;281(1):R133–9.PubMed

14.

Smith HJ, Mukerji P, Tisdale MJ. Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss. Cancer Res. 2005;65(1):277–83.PubMed

15.

Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci J Virtual Libr. 2001;6:D164–74.CrossRef

16.

Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer. 2005;5(4):285–96.PubMedCrossRef

17.

Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology. 2009;23(6):488–96.PubMedCentralPubMed

18.

Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2000;2:CD001215.

19.

Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5(8):2192–7.

20.

Houghton ANLS, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch CHA, Sober A, Soong S, editors. Cutaneous Melanoma. 2nd ed. Philadelphia: JB Lippincott Company; 2003. p. 498.

21.

Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47(22):5846–52.PubMed

22.

Lexi-Comp Online™. Temozolomide: drug information. Hudson, Ohio: Lexi-comp, Inc. 2012 Accessed 25 July 2012.

23.

Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47(10):1476–83.PubMedCrossRef

24.

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(1):158–66.

25.

Williams KV, Bertoldo A, Mattioni B, Price JC, Cobelli C, Kelley DE. Glucose transport and phosphorylation in skeletal muscle in obesity: insight from a muscle-specific positron emission tomography model. J Clin Endocrinol Metab. 2003;88(3):1271–9.PubMedCrossRef

26.

Tanaka S, Ikeda K, Uchiyama K, Iwamoto T, Sanayama Y, Okubo A, et al. [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatology. 2013;52(7):1271–8.PubMedCrossRef

27.

Rudroff T, Kalliokoski KK, Block DE, Gould JR, Klingensmith WC 3rd, Enoka RM. PET/CT imaging of age- and task-associated differences in muscle activity during fatiguing contractions. J Appl Physiol. 2013;114(9):1211–9.PubMedCentralPubMedCrossRef

28.

Khandelwal AR, Takalkar AM, Lilien DL, Ravi A. Skeletal muscle metastases on FDG PET/CT imaging. Clin Nucl Med. 2012;37(6):575–9.PubMedCrossRef

29.

Tai SJ, Liu RS, Kuo YC, Hsu CY, Chen CH. Glucose uptake patterns in exercised skeletal muscles of elite male long-distance and short-distance runners. Chin J Physiol. 2010;53(2):91–8.PubMedCrossRef

30.

Aydin A, Hickeson M, Yu JQ, Zhuang H, Alavi A. Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with chronic obstructive pulmonary disease. Clin Nucl Med. 2005;30(3):159–64.PubMedCrossRef

31.

Matthews R, Shrestha P, Franceschi D, Relan N, Kaloudis E. Head and neck cancers: post-therapy changes in muscles with FDG PET-CT. Clin Nucl Med. 2010;35(7):494–8.PubMedCrossRef

32.

Wang YC, Hsieh TC, Chen SW, Yen KY, Kao CH, Chang KC. Concurrent chemo-radiotherapy potentiates vascular inflammation: increased FDG uptake in head and neck cancer patients. JACC Cardiovasc Imaging. 2013;6(4):512–4.PubMedCrossRef

33.

D’Agata F, Costa T, Caroppo P, Baudino B, Cauda F, Manfredi M, et al. Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network. EJNMMI Res. 2013;3(1):22.PubMedCentralPubMedCrossRef

34.

Baudino B, D’Agata F, Caroppo P, Castellano G, Cauda S, Manfredi M, et al. The chemotherapy long-term effect on cognitive functions and brain metabolism in lymphoma patients. Q J Nucl Med Mol Imaging. 2012;56(6):559–68.PubMed

35.

Goethals I, Hoste P, De Vriendt C, Smeets P, Verlooy J, Ham H. Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(3):462–7.PubMedCrossRef

36.

Bural G, Torigian D, Houseni M, Chamroonrat W, Alavi A. Effects of systemic chemotherapy on cervical spinal cord FDG uptake. J Nucl Med. 2007;48(Supplement 2):250P.

37.

Kawano T, Suzuki A, Ishida A, Takahashi N, Lee J, Tayama Y, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imaging. 2004;31(6):831–6.PubMedCrossRef

38.

Torigian DA, Lopez RF, Alapati S, Bodapati G, Hofheinz F, van den Hoff J, et al. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. Hellenic J Nucl Med. 2011;14(1):8–14.

Title: FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma
Authors: Marcus D. Goncalves
Abass Alavi
Drew A. Torigian
Publication date: 01-05-2014
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 4/2014
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-014-0822-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma

Abstract

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology Recommendations

Assessment of [18F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor

18F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer

Modulation transfer function assessment in parallel beam and fan beam collimators with square and cylindrical holes

Performance measurement of PSF modeling reconstruction (True X) on Siemens Biograph TruePoint TrueV PET/CT

Clinical impact of “true whole-body” 18F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities